Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ERB-041 · 4 trials · 7 indications
| Name | Type | Description |
|---|---|---|
| ERB-041 | DRUG | - |
Inclusion Criteria: * Surgical diagnosis of endometriosis within the last 10 years * Sexually active, nonpregnant, nonlactating women (18-45 years) with regular menstrual cycles who are willing to use non-hormonal contraception Exclusion Criteria: * Conditions requiring the use of chronic pain th...
ERB-041 is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE) for inflammatory and pain-related conditions. It has been studied in Crohn's disease, endometriosis, dysmenorrhea, and long QT syndrome. It is not approved and remains in clinical development.
ERB-041 has been studied for Crohn's disease, endometriosis, dysmenorrhea, and long QT syndrome. Clinical trials evaluated it for reducing symptoms associated with endometriosis in reproductive-aged women and for treating active Crohn's disease. It is investigational and has not been approved for any indication.
Pfizer, Inc. (NYSE: PFE) is the developer of ERB-041. The company sponsored the clinical trials evaluating the drug in endometriosis, Crohn's disease, and cardiac repolarization.
ERB-041 has been tested in Phase 1 and Phase 2 clinical trials. The Phase 1 studies evaluated it in active Crohn's disease and in healthy subjects for cardiac repolarization effects. Phase 2 studies evaluated it in endometriosis and dysmenorrhea. It is investigational and not approved.
ERB-041 has completed four clinical trials: NCT00318500 (Phase 2, endometriosis, 150 participants), NCT00316459 (Phase 1, cardiac repolarization, 64 participants), NCT00245947 (Phase 1, Crohn's disease, 22 participants), and NCT00110487 (Phase 2, endometriosis, 200 participants). All trials are completed.